Gilead Sciences’s Buy Rating Reaffirmed at Deutsche Bank (GILD)
Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by stock analysts at Deutsche Bank in a report issued on Friday, Stock Ratings Network reports. They currently have a $77.00 price objective on the stock. Deutsche Bank’s target price suggests a potential upside of 10.27% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday, October 14th. Finally, analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, September 25th. They now have a $66.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $67.91.
Gilead Sciences (NASDAQ:GILD) traded down 1.60% on Friday, hitting $68.71. 4,326,319 shares of the company’s stock traded hands. Gilead Sciences has a 52-week low of $30.955 and a 52-week high of $64.04. The stock has a 50-day moving average of $60.42 and a 200-day moving average of $53.59. The company has a market cap of $105.2 billion and a P/E ratio of 39.08.
In other Gilead Sciences news, EVP Norbert Bischofberger sold 90,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $62.54, for a total value of $5,628,600.00. Following the completion of the sale, the executive vice president now directly owns 2,159,643 shares in the company, valued at approximately $135,064,073. The transaction was disclosed in a filing with the SEC, which is available at this link.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.